*Supplementary Materials*

Efficacy and Safety of Neoadjuvant Gemcitabine plus Nab-Paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Cancer–a Systematic Review and Meta-Analysis

Marko Damm, Ljupcho Efremov, Benedikt Birnbach, Gretel Terrero, Jörg Kleeff, Rafael Mikolajczyk, Jonas Rosendahl, Patrick Michl and Sebastian Krug

Figure S1. Forest plots showing the pooled proportions of resections and R0 resections (defined as the absence of tumor at the margin or a minimum distance between tumor and margin of >1 mm) of prospective studies (*n* = 396, [31,33,36,38–42,46]). Due to heterogeneity among studies, a random effects model was used. The proportions of the R0 resections were calculated on the basis of the total number of patients treated with neoadjuvant gemcitabine and nab-paclitaxel in the intention-to-treat population. The red dotted line and blue diamond shape indicate the overall pooled proportions (resection rate or R0 resection rate) including overall 95% confidence intervals (95% CI). The individual proportions of each study including 95% CI are shown in the column "ES (95% CI)". The graphical representation corresponds to the black squares and lines whereby the size of the squares reflects the respective weighting in the analysis. Abbreviation: ES, effect size.

Figure S2. Funnel plot of all studies included in the meta-analysis (*n* = 19, [26,28–31,33–46]). Circles represent included studies. The plot displays the results (x-axis) and the precision of the studies (y-axis). The line in the center indicates the summary proportion. The two dotted lines represent the 95% confidence limits. Symmetry about the pooled proportion line is suggestive of absence of publication bias. Abbreviations: ES, effect size; se(ES), standard error of effect size.

Table S1. Grade ≥ 3 adverse events of included studies [26–46].

No.	Study	n	Neutropenia		Febrile Neutropenia		Anemia		Thrombocytopenia		Infection		Neuropathy		Death	
			n	%	n	%	n	%	n	%	n	%	n	%	n	%
1	Chapman et al., 2018	37	5	14	NR	NR	NR	NR	2	5	0	0	1	3	NR	NR
2	Dhir et al., 2018	120	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
3	Gemenetzis et al., 2019	87	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
4	Gulhati et al., 2019	54	NR	12	NR	3	NR	1	NR	NR	NR	NR	NR	1	NR	NR
5	Ielpo et al., 2017 *1	45	4	9	NR	NR	0	0	2	4	6	13	0	0	0	0
6	Kondo et al., 2017	16	3	19	0	0	0	0	0	0	1	6	0	0	0	0
7	Macedo et al., 2019	91	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
8	Maggino et al., 2019	123	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
9	Miyasaka et al., 2019	31	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
10	Napolitano et al., 2019	21	1	5	NR	NR	1	5	1	5	NR	NR	1	5	NR	NR
11	Okada et al., 2017	10	9	90	0	0	1	10	2	20	NR	NR	1	10	0	0
12	Peterson et al., 2018	26	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
13	Philip et al., 2020	106	35	33	4	4	12	11	4	4	NR	NR	5	5	0	0
14	Reni et al., 2016	24	13	54	1	4	3	13	0	0	NR	NR	0	0	0	0
15	Reni et al., 2018	54	38	70	NR	NR	6	11	3	6	6	11	5	9	0	0
16	Shabason et al., 2018 *2	9	1	11	NR	NR	1	11	NR	NR	NR	NR	2	22	NR	NR
17	Takahashi et al., 2018 *3	30	23	77	1	3	1	3	1	3	NR	NR	1	3	0	0
18	Templeton et al., 2020	10	3	30	2	20	NR	NR	NR	NR	NR	NR	1	10	NR	NR
19	Tsujimoto et al., 2019	30	22	73	0	0	2	7	NR	NR	1	3	0	0	0	0
20	Weniger et al., 2020	21	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
21	Yamada et al., 2018	12	7	58	0	0	0	0	1	8	NR	NR	0	0	0	0

*1 No separate results on toxicity for borderline resectable pancreatic cancer (includes resectable patients, n = 19). *2 Four patients were excluded because of progress after induction therapy. *3 Eight patients were excluded because of toxicity of the induction therapy. Abbreviations: NR = not reported.

Table S2. Quality assessment of retrospective cohort studies using the Newcastle-Ottawa Scale (NOS).

No	Study	Selection 1	Selection 2	Selection 3	Selection 4	Comparability	Outcome 1	Outcome 2	Outcome 3	NOS (Overall)	Quality *
1	Chapman et al., 2018 [26]	1	1	1	1	2	1	1	0	8	good
2	Dhir et al., 2018 [27]	1	1	1	1	2	1	1	1	9	good
3	Gemenetzis et al., 2019 [28]	1	1	1	1	1	1	1	1	8	moderate
4	Gulhati et al., 2019 [29]	1	1	1	1	1	1	1	0	7	moderate
5	Ielpo et al., 2017 [30]	1	1	1	1	1	1	1	0	7	moderate
6	Macedo et al., 2019 [32]	1	1	1	1	2	1	1	1	9	good
7	Maggino et al., 2019 [33]	1	1	1	1	2	1	1	1	9	good
8	Miyasaka et al., 2019 [34]	1	1	1	1	1	1	1	0	7	moderate
9	Napolitano et al., 2019 [35]	1	1	1	1	1	1	1	0	7	moderate
10	Peterson et al., 2018 [37]	1	1	1	1	1	1	1	0	7	moderate
11	Templeton et al., 2020 [43]	1	1	1	1	0	1	1	0	6	poor
12	Tsujimoto et al., 2019 [44]	1	1	1	1	1	1	1	0	7	moderate
13	Weniger et al., 2020 [45]	1	1	1	1	1	1	1	0	7	moderate

*A study was scored as good quality if at least 3 points for selection, 1 for comparability and 2 for outcome were achieved. Moderate quality was defined as 2 points for selection, 1 point for comparability or 1 point for outcome. Studies of poor quality reached 1 point for selection, no points for comparability or 1 point in outcome.

Table S3. Risk of bias assessment of clinical trials using the Cochrane Collaboration's tool.

No	Study	Random Sequence Generation (Selection Bias)	Allocation Concealment (Selection Bias)	Blinding of Participants And Personnel (Performance Bias)	Blinding Of Outcome Assessment (Detection Bias)	Incomplete Outcome Data (Attrition Bias)	Selective Reporting (Reporting Bias)	Other Bias	Overall Bias
1	Kondo et al., 2017 [31]	High risk	High risk	High risk	High risk	Low risk	Low risk	Unclear risk	High risk
2	Okada et al., 2017 [36]	High risk	High risk	High risk	High risk	Low risk	Low risk	Unclear risk	High risk
3	Philip et al. 2020 [38]	High risk	High risk	High risk	High risk	Low risk	Low risk	Unclear risk	High risk
4	Reni et al., 2016 [39]	High risk	High risk	High risk	High risk	Low risk	Low risk	Unclear risk	High risk
5	Reni et al., 2018 [40]	Low risk	Unclear risk	High risk	High risk	Low risk	Low risk	Unclear risk	Unclear risk
6	Shabason et al., 2018 [41]	High risk	High risk	High risk	High risk	Low risk	Low risk	Unclear risk	High risk
7	Takahashi et al., 2018 [42]	High risk	High risk	High risk	High risk	Low risk	Low risk	Unclear risk	High risk
8	Yamada et al., 2018 [46]	High risk	High risk	High risk	High risk	Low risk	Low risk	Unclear risk	High risk